作为协议的一部分，Valo还将从诺和诺德获得1.9亿美元的综合资金，这包括预付款、股权投资以及潜在的近期里程碑付款。Danish pharmaceutical giant Novo Nordisk and artificial intelligence biotech company Valo Health announced on Wednesday an expanded collaboration aimed at speeding up research and development of new treatments for cardiometabolic diseases.
The Zhitong Finance App learned that Danish pharmaceutical giant Novo Nordisk (NVO.US) and artificial intelligence biotech company Valo Health announced an expansion of cooperation on Wednesday to accelerate research and development of new treatments for cardiometabolic diseases. According to the latest agreement, the two sides will jointly promote 20 new drug projects, covering cardiovascular disease, obesity, and type 2 diabetes. Valo is expected to receive a total of about 4.6 billion US dollars in milestone payments and other R&D funding and royalties.
The cooperation agreement initially reached in 2023 focused on cardiovascular diseases, and Novo Nordisk and Valo agreed to jointly advance as many as 11 drug projects. At the time, Valo was entitled to milestone payments of up to $2.7 billion. The revised agreement significantly expanded the scope of cooperation, adding 9 new projects focusing on the treatment of obesity, type 2 diabetes, and cardiovascular disease.
As part of the agreement, Valo will also receive $0.19 billion in comprehensive funding from Novo Nordisk, which includes prepayments, equity investments, and potential near-term milestone payments.
Marcus Schindler, head of science at Novo Nordisk, expressed high satisfaction with the progress of the first year of cooperation between the two sides and emphasized expectations for expanding the scope of cooperation and focusing on more disease fields.
